Poor
Not Aligned
Patient Risk:
Medium
Summary
Multiple substantive claims (Phase 3 OS/PFS results and specific dosing) are not supported by the provided FDA label excerpts; additional mechanistic statements include unsupported/overreaching details. Only formulation/IV administration and core topoisomerase inhibitor mechanism elements are clearly supported.
Category Scores
Accurate Statements
Onivyde is formulated as an irinotecan liposome for intravenous use.
11 DESCRIPTION (irinotecan hydrochloride trihydrate into a liposomal dispersion for intravenous use)
Irinotecan in Onivyde is a topoisomerase inhibitor (topoisomerase 1 inhibitor).
11 DESCRIPTION and 12.1 Mechanism of Action (topoisomerase 1 inhibitor; binding to topoisomerase 1-DNA complex preventing re-ligation)
Irinotecan and its active metabolite SN-38 bind to the topoisomerase 1-DNA complex and prevent re-ligation, leading to DNA damage and cell death.
12.1 Mechanism of Action
Onivyde is indicated for metastatic pancreatic adenocarcinoma in specific combination regimens (not as a single agent).
1 INDICATIONS AND USAGE; limitation of use: not indicated as a single agent
Unsupported Statements
In a Phase 3 trial, Onivyde in combination with a fluoropyrimidine-based chemotherapy regimen significantly improved overall survival compared with the fluoropyrimidine regimen alone.
No Phase 3 efficacy/survival comparison details are present in the provided label excerpts.
In the Phase 3 trial, median overall survival was 6.1 months with Onivyde versus 4.2 months without Onivyde.
No median OS values are present in the provided label excerpts.
In the Phase 3 trial, progression-free survival was improved in the Onivyde arm.
No PFS result statements are present in the provided label excerpts.
The recommended dose of Onivyde is 80 mg/m² once every two weeks.
The provided label excerpts include dosage modification tables but do not state this recommended dosing/schedule.
Common adverse reactions reported for Onivyde in clinical trials include diarrhea, fatigue, nausea, vomiting, decreased appetite, and stomatitis.
The provided excerpts do not include the Adverse Reactions section listing common adverse reactions.
Liposomal encapsulation of irinotecan allows for sustained release of irinotecan.
No sustained-release statement is present in the provided label excerpts.
Sustained release may prolong irinotecan exposure in the tumor microenvironment and potentially enhance antitumor activity.
No tumor microenvironment exposure or antitumor enhancement statements are present in the provided label excerpts.
DNA topoisomerase I is essential for DNA replication and repair.
The provided mechanism excerpt does not explicitly state essentiality for replication/repair.
Onivyde’s patent landscape is complex, with patents covering drug formulation, manufacturing, and methods of use.
No patent/intellectual property information is present in the provided label excerpts.
Ongoing clinical trials continue to explore the efficacy and safety of Onivyde in various settings and in combination with other agents for pancreatic cancer.
No ongoing clinical trial statements are present in the provided label excerpts.
Ongoing clinical trials continue to explore the efficacy and safety of Onivyde in combination with other agents potentially for other solid tumors.
No ongoing clinical trial statements or other solid tumor expansion statements are present in the provided label excerpts.
Contradictions
Low
AI Statement
The recommended dose of Onivyde is 80 mg/m² once every two weeks.
Label Reference
2 DOSAGE AND ADMINISTRATION (provided excerpts show dose modification tables for specific regimens/doses, but do not provide/verify the stated recommended starting dose and schedule).
Important Omissions
Dose administration details required to accurately convey labeling dosing (e.g., regimen-specific recommended dose, schedule, and regimen context) are not provided/verified for the claimed 80 mg/m² once-every-two-weeks dosing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported specific dosing and unsupported adverse-reaction frequency claims could misinform safe use and risk communication; efficacy result quantification (OS/PFS) also lacks label support in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Substantive efficacy outcomes and a specific recommended dosing regimen are stated without support in the provided FDA label excerpts.
Suggested Improvement
Restrict claims to information actually present in the provided label excerpts (e.g., approved combination indications, IV liposomal formulation, and the mechanism of action language). Remove or clearly qualify unsupported Phase 3 OS/PFS numbers, unsupported dosing schedules, and unsupported lists of 'common' adverse reactions unless the corresponding label text is provided.